Rank (Similarity) |
PMID (PMCID) |
|
---|---|---|
1 (17.5%) |
21507038 |
Disseminated superficial actinic porokeratosis treated effectively with topical imiquimod 5% cream. Arun B, Pearson J, Chalmers R. Clin Exp Dermatol. 2011;36(5):509-11. |
Erythema Scarring | ||
Administration, Cutaneous Aminoquinolines Drug Administration Schedule Homo sapiens Interferon Inducers Male Porokeratosis | ||
2 (4.0%) |
29630163 |
A report and follow up of a patient with disseminated superficial actinic porokeratosis (DSAP) undergoing novel systemic treatment with palifermin (a keratinocyte growth factor) during chemotherapy. Howard M, Hall A. Dermatol Online J. 2018;24(2):. |
Basal cell carcinoma | ||
SERPINB3 | ||
Central Nervous System Neoplasms Follow-Up Studies Homo sapiens Lymphoma Male Porokeratosis Rosacea | ||
2 (4.0%) |
28976625 |
Amelanotic melanoma arising within a lesion of disseminated superficial actinic porokeratosis: An unusual presentation leading to a novel therapeutic approach. Al-Haseni A, Chitgopeker P, Ho JD, Goldberg LJ, Sahni D. Dermatol Ther. 2018;31(1):. |
Melanoma | ||
Administration, Cutaneous Antimetabolites, Antineoplastic Bandage Biopsy Females Homo sapiens Melanoma, Amelanotic Neoplastic Cell Transformation Porokeratosis Precancerous Conditions Skin Neoplasms | ||
2 (4.0%) |
28922948 |
Clinical and Dermoscopic Features of Pigmented Disseminated Superficial Actinic Porokeratosis: Case Report and Literature Review. Sotoodian B, Mahmood MN, Salopek TG. J Cutan Med Surg. 2018;22(2):229-231. |
Erythematous papule | ||
Back Biopsy Dermoscopy Homo sapiens Male Porokeratosis Skin Sunlight | ||
2 (4.0%) |
28398427 |
Disseminated superficial actinic porokeratosis treated with ingenol mebutate gel 0.05. Anderson I, Routt ET, Jim On SC. Cutis. 2017;99(3):E36-E39. |
Actinic keratosis | ||
Administration, Cutaneous Adult Dermatologic Agents Diterpenes Females Homo sapiens Porokeratosis | ||
2 (4.0%) |
27468973 |
Disseminated superficial actinic porokeratosis (DSAP): significant improvement after local administration of calcipotriol/betamethasone gel? Tchernev G, Chokoeva AA, Ivanova B, Mangarov H, Vidolova NG. Wien Med Wochenschr. 2017;167(3-4):85-88. |
Basal cell carcinoma | ||
Administration, Topical Aged, 80 and over Combination Drug Therapy Drug Administration Schedule Females Homo sapiens Leg Dermatoses Porokeratosis | ||
2 (4.0%) |
27086492 |
Linear porokeratosis with multiple squamous cell carcinomas successfully treated by electrochemotherapy. Sommerlad M, Lock A, Moir G, McGregor J, Bull R, Cerio R, Harwood C. Br J Dermatol. 2016;175(6):1342-1345. |
Squamous cell carcinoma | ||
Antibiotics, Antineoplastic Bowen's Disease Electrochemotherapy Homo sapiens Male Middle Aged Neoplastic Cell Transformation Porokeratosis Skin Neoplasms | ||
2 (4.0%) |
25800103 |
Eruptive disseminated porokeratosis associated with corticosteroid-induced immunosuppression. Bednarek R, Ezra N, Toubin Y, Linos K, Mousdicas N. Clin Exp Dermatol. 2015;40(7):753-6. |
Asthma | ||
Adrenal Cortex Hormones Adult Females Homo sapiens Immunosuppressive Agents Porokeratosis | ||
2 (4.0%) |
22148029 (3229955) |
Squamous Cell Carcinoma Developing within Lesions of Disseminated Superficial Actinic Porokeratosis. Lee HR, Han TY, Son SJ, Lee JH. Ann Dermatol. 2011;23(4):536-8. |
Squamous cell carcinoma | ||
2 (4.0%) |
21933257 |
Exclusive facial porokeratosis: histopathologically showing follicular cornoid lamellae. Lee Y, Choi EH. J Dermatol. 2011;38(11):1072-5. |
Macule | ||
Administration, Topical Adult Face Females Homo sapiens Porokeratosis |
Total: 4
HPO ID | Term | Frequency |
---|---|---|
HP:0200044 | Porokeratosis | Very frequent (99-80%) |
HP:0000992 | Cutaneous photosensitivity | Frequent (79-30%) |
HP:0000989 | Pruritus | Occasional (29-5%) |
HP:0002860 | Squamous cell carcinoma | Occasional (29-5%) |
Total: 5
HPO ID | Term | # of case reports |
---|---|---|
HP:0002860 | Squamous cell carcinoma | 2 |
HP:0200034 | Papule | 2 |
HP:0002664 | Neoplasm | 1 |
HP:0020073 | Hypopigmented macule | 1 |
HP:0200039 | Pustule | 1 |